DXNVX Launches Integrated Companion Diagnostic Development Service

DXVX announced on the 18th that it is launching an integrated companion diagnostic service utilizing various types of gene panels and entering the companion diagnostics market, which is expected to grow to a global scale of 10 trillion KRW.

Companion diagnostics (CDx) is a diagnostic technique used to predict whether a specific drug will be effective for a patient. In 2014, the U.S. FDA recommended the use of companion diagnostics in clinical trials and issued mandatory guidelines for new drug development and companion diagnostics.

Integrating companion diagnostics into new drug development has advantages such as tripling the success rate of new drug development and reducing development costs to one-third. Accordingly, many domestic and international pharmaceutical companies developing new drugs, including anticancer drugs, are entering an era where it is essential to jointly develop companion diagnostics for target biomarkers with diagnostic companies from the early development stage through clinical and commercialization phases.

DXVX plans to lead the trend of integrated companion diagnostics encompassing various existing companion diagnostic analysis methods such as NGS, FISH, and PCR by leveraging its top-tier genome analysis technology expertise in Korea, and to target the market with differentiated companion diagnostic products and services.

DXVX possesses an AI-based digital database system utilizing over 400,000 clinical genome analysis data and expertise in developing and manufacturing validated PCR and immunodiagnostic kits. Through this, it can provide customized services reflecting client demands such as cell tissue or blood samples required for companion diagnostics.

Additionally, recently joined global clinical and RA experts enable the company to offer differentiated integrated all-in-one companion diagnostic development solutions that comprehensively cover global clinical and regulatory approval services compared to other companies.

A company representative stated, “Based on long-accumulated genome analysis technology know-how and clinical analysis data of rare diseases, cancer, and various adult disease genomes, we will lead the market with innovative integrated companion diagnostic services. We will expand companion diagnostic service sales from nationwide hospital networks to research institutes and pharmaceutical companies and further extend services to the global market.”

Currently, DXVX receives development requests from startups and bio-venture companies developing anticancer new drugs as well as pharmaceutical bio companies, and is preparing to launch services for overseas bio-pharmaceutical companies. It is also in discussions with Professor Antonio Gasbarini of Italy’s Gemelli Hospital regarding the operation of a local companion diagnostics center in Italy. Through this, DXVX, which has declared new drug development, is expected to operate a virtuous cycle R&D investment model by utilizing the companion diagnostics business as a new revenue source to invest in new drug development research funds.

Meanwhile, according to the report (Global Companion Diagnostics Market) by the global specialized research firm Technavio, the companion diagnostics market is expected to grow at an annual rate of over 26%, reaching a scale of 8.3 billion USD (approximately 10 trillion KRW) by 2024.

This content was produced with the assistance of AI translation services.